As a development-stage company, Cutanea's business strategy is to identify and in-license promising dermatological product opportunities for which discovery research and preclinical development are substantially complete. We intend to advance the development of these opportunities aggressively, while maximizing our intellectual property estate and leveraging our technologies into additional therapeutic indications. Based on where we see the greatest opportunity for creating the greatest value for patients, our shareholders, and our company, we will evaluate strategies to market the products ourselves, or out-license them to other dermatology companies.
